Ferric carboxymaltose for iron deficiency in patients with heart failure: a systematic review and meta-analysis

References

• Cohen-Solal A, Damy T, Terbah M, et al. High prevalence of iron deficiency in patients with acute decompensated heart failure. Eur J Heart Fail. 2014;16(9):984–991. doi:10.1002/ejhf.139
   PubMed Web of Science ®Google Scholar
• Van Aelst LNL, Abraham M, Sadoune M, et al. Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up. Eur J Heart Fail. 2017;19(8):1075–1076. doi:10.1002/ejhf.837
   PubMed Web of Science ®Google Scholar
• Rocha BML, Cunha GJL, Menezes Falcão LF. The burden of iron deficiency in heart failure: therapeutic approach. J Am Coll Cardiol. 2018;71(7):782–793. doi:10.1016/j.jacc.2017.12.027
   PubMed Web of Science ®Google Scholar
• von Haehling S, Ebner N, Evertz R, et al. Iron deficiency in heart failure: an overview. JACC Heart Fail. 2019;7(1):36–46. doi:10.1016/j.jchf.2018.07.015
   PubMed Web of Science ®Google Scholar
• Jankowska EA, Kasztura M, Sokolski M, et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J. 2014;35(36):2468–2476. doi:10.1093/eurheartj/ehu235
   PubMed Web of Science ®Google Scholar
• Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31(15):1872–1880. doi:10.1093/eurheartj/ehq158
   PubMed Web of Science ®Google Scholar
• Rangel I, Gonçalves A, de Sousa C, et al. Iron deficiency status irrespective of anemia: a predictor of unfavorable outcome in chronic heart failure patients. Cardiology. 2014;128(4):320–326. doi:10.1159/000358377
   PubMed Web of Science ®Google Scholar
• Sama IE, Woolley RJ, Nauta JF, et al. A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure. Eur J Heart Fail. 2020;22(5):821–833. doi:10.1002/ejhf.1811
   PubMed Web of Science ®Google Scholar
• Severino P, D'Amato A, Pucci M, et al. Ischemic heart disease and heart failure: role of coronary ion channels. Int J Mol Sci. 2020;21(9):3167. doi:10.3390/ijms21093167
   PubMed Web of Science ®Google Scholar
• Gajanana D, Shah M, Junpapart P, et al. Mortality in systolic heart failure revisited: ischemic versus non-ischemic cardiomyopathy. Int J Cardiol. 2016;224:15–17. doi:10.1016/j.ijcard.2016.08.316
   PubMed Web of Science ®Google Scholar
• Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the national heart, lung, and blood institute. Circulation. 2009;119(24):3070–3077. doi:10.1161/CIRCULATIONAHA.108.815944
   PubMed Web of Science ®Google Scholar
• Silverdal J, Sjöland H, Bollano E, et al. Prognostic impact over time of ischaemic heart disease vs. non-ischaemic heart disease in heart failure. ESC Heart Fail. 2020;7(1):264–273. doi:10.1002/ehf2.12568
   PubMed Web of Science ®Google Scholar
• Vedin O, Lam CSP, Koh AS, et al. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circ Heart Fail. 2017;10(6):e003875. doi:10.1161/CIRCHEARTFAILURE.117.003875
   PubMed Web of Science ®Google Scholar
• Bakogiannis C, Briasoulis A, Mouselimis D, et al. Iron deficiency as therapeutic target in heart failure: a translational approach. Heart Fail Rev. 2020;25(2):173–182. doi:10.1007/s10741-019-09815-z
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368
   PubMed Web of Science ®Google Scholar
• Martin-Malo A, Borchard G, Flühmann B, et al. Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients. ESC Heart Fail. 2019;6(2):241–253. doi:10.1002/ehf2.12400
   PubMed Web of Science ®Google Scholar
• Núñez J, Miñana G, Cardells I, et al. Noninvasive imaging estimation of myocardial iron repletion following administration of intravenous iron: the myocardial-IRON trial. J Am Heart Assoc. 2020;9(4):e014254. doi:10.1161/JAHA.119.014254
   PubMed Web of Science ®Google Scholar
• Del Canto I, Santas E, Cardells I, et al. Short-term changes in left and right ventricular cardiac magnetic resonance feature tracking strain following ferric carboxymaltose in patients with heart failure: a substudy of the myocardial-IRON trial. J Am Heart Assoc. 2022;11(7):e022214. doi:10.1161/JAHA.121.022214
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34. doi:10.1016/j.jclinepi.2009.06.006
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
   PubMed Web of Science ®Google Scholar
• Higgins J, Thompson S, Deeks J, et al. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327:557–560. doi:10.1136/bmj.327.7414.557
   PubMed Web of Science ®Google Scholar
• Borenstein M, Hedges LV, Higgins JP, et al. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97–111. doi:10.1002/jrsm.12
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Egger M, Moher D, Boutron I. Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editors. Cochrane Handbook for Systematic Reviews of Interventions Version. 2017. www.training.cochrane.org/handbook
   Google Scholar
• Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13(6):368–378. doi:10.1038/nrcardio.2016.25
   PubMed Web of Science ®Google Scholar
• Stretti L, Zippo D, Coats AJS, et al. A year in heart failure: an update of recent findings. ESC Heart Fail. 2021;8(6):4370–4393. doi:10.1002/ehf2.13760
   PubMed Web of Science ®Google Scholar
• Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575–582.e3. doi:10.1016/j.ahj.2013.01.017
   PubMed Web of Science ®Google Scholar
• Loncar G, Obradovic D, Thiele H, et al. Iron deficiency in heart failure. ESC Heart Fail. 2021;8(4):2368–2379. doi:10.1002/ehf2.13265
   PubMedGoogle Scholar
• Melenovsky V, Petrak J, Mracek T, et al. Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis. Eur J Heart Fail. 2017;19(4):522–530. doi:10.1002/ejhf.640
   PubMed Web of Science ®Google Scholar
• Dunn LL, Suryo Rahmanto Y, Richardson DR. Iron uptake and metabolism in the new millennium. Trends Cell Biol. 2007;17(2):93–100. doi:10.1016/j.tcb.2006.12.003
   PubMed Web of Science ®Google Scholar
• Rouault TA, Tong WH. Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat Rev Mol Cell Biol. 2005;6(4):345–351. doi:10.1038/nrm1620
   PubMed Web of Science ®Google Scholar
• Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc Res. 2009;81(3):412–419. doi:10.1093/cvr/cvn301
   PubMed Web of Science ®Google Scholar
• Jankowska EA, von Haehling S, Anker SD, et al. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J. 2013;34(11):816–829. doi:10.1093/eurheartj/ehs224
   PubMed Web of Science ®Google Scholar
• Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Hematol. 2009;122(2–3):78–86. doi:10.1159/000243791
   PubMed Web of Science ®Google Scholar
• Eivazi M, Mutharasan RK, Cleveland E, et al. Outcome of titrating guideline directed medical therapy in heart failure patients at 90-day post-hospital discharge. Journal of Cardiac Failure. 2019;25:S138. doi:10.1016/j.cardfail.2019.07.399
   Web of Science ®Google Scholar
• Beck-da-Silva L, Piardi D, Soder S, et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol. 2013;168(4):3439–3442. doi:10.1016/j.ijcard.2013.04.181
   PubMed Web of Science ®Google Scholar
• Lewis GD, Malhotra R, Hernandez AF, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA. 2017;317(19):1958–1966. doi:10.1001/jama.2017.5427
   PubMed Web of Science ®Google Scholar
• McDonagh T, Damy T, Doehner W, et al. Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. Eur J Heart Fail. 2018;20(12):1664–1672. doi:10.1002/ejhf.1305
   PubMed Web of Science ®Google Scholar
• Butler J, Khan MS, Friede T, et al. Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency. Eur J Heart Fail. 2022;24(5):821–832. doi:10.1002/ejhf.2478
   PubMed Web of Science ®Google Scholar
• Dhoot S, Mittal S, Singh SP, et al. Effect of ferric-carboxy maltose on oxygen kinetics and functional status in heart failure patients with iron deficiency. Future Sci OA. 2020;6(5):Fso467. doi:10.2144/fsoa-2019-0156
   PubMed Web of Science ®Google Scholar
• Bourguignon S, Faller M, Champs FO, et al. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France. ESC Heart Fail. 2019;6(3):559–569. doi:10.1002/ehf2.12432
   PubMed Web of Science ®Google Scholar
• McDonagh T, Macdougall IC. Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? Eur J Heart Fail. 2015;17(3):248–262. doi:10.1002/ejhf.236
   PubMed Web of Science ®Google Scholar
• Mollace A, Macrì R, Mollace R, et al. Effect of ferric carboxymaltose supplementation in patients with heart failure with preserved ejection fraction: role of attenuated oxidative stress and improved endothelial function. Nutrients. 2022;14(23):5057. doi:10.3390/nu14235057
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Ponikowski P, Stack AG, et al. Ferric carboxymaltose in iron-deficient patients with hospitalized heart failure and reduced kidney function. Clin J Am Soc Nephrol. 2023;18(9):1124–1134. doi:10.2215/CJN.0000000000000223
   PubMed Web of Science ®Google Scholar
• Khan MS, Usman MS, von Haehling S, et al. Ferric carboxymaltose for the treatment of iron-deficient heart failure patients: a systematic review and meta-analysis. ESC Heart Fail. 2020;7(6):3392–3400. doi:10.1002/ehf2.13146
   PubMed Web of Science ®Google Scholar
• Martens P, Dupont M, Dauw J, et al. The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial. Eur Heart J. 2021;42(48):4905–4914. doi:10.1093/eurheartj/ehab411
   PubMed Web of Science ®Google Scholar
• Harrington J, Mentz RJ, Rockhold FW, et al. Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial. Am Heart J. 2023;266:25–31. doi:10.1016/j.ahj.2023.08.005
   PubMed Web of Science ®Google Scholar
• Yeo TJ, Yeo PSD, Hadi FA, et al. Single-dose intravenous iron in Southeast Asian heart failure patients: a pilot randomized placebo-controlled study (PRACTICE-ASIA-HF). ESC Heart Fail. 2018;5(2):344–353. doi:10.1002/ehf2.12250
   PubMed Web of Science ®Google Scholar
• van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017;136(15):1374–1383. doi:10.1161/CIRCULATIONAHA.117.027497
   PubMed Web of Science ®Google Scholar
• Geng Q, Li S, Wang Z, et al. Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: a meta-analysis of randomized controlled trials. Int J Cardiol. 2019;293:159–164. doi:10.1016/j.ijcard.2019.05.048
   PubMed Web of Science ®Google Scholar